Understood, but our speculations based on unspecified examples are going to be even less informed. I'm happy to entertain well-reasoned ones, though. The reason I pointed to #2 is because, as has been pointed out here, the manufacturing practices are a much harder area to optimize with a mixture like Lovenox versus your standard small molecule generic. GMP here could be the ultimate bin for all sorts of underlying problems. Or not.